Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04142320 · ClinicalTrials.gov registry record · NA

Closed-loop Optimized rTMS for Depression

A NA study of Major Depressive Disorder, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
54
Enrollment target
1
Study location

NCT04142320: Recruiting NA study of Major Depressive Disorder, sponsored by Stanford University.

NCT04142320 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 54 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04142320, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

Targeted and individualized treatments for mental health disorders are critically needed. Repetitive transcranial magnetic stimulation (rTMS) represents the front-line of new and innovative approaches to normalizing dysfunctional brain networks in those with mental illness. rTMS is FDA-approved for depression and obsessive-compulsive disorder with clinical trials underway for PTSD and addiction, among others. However, remission rates are suboptimal and ideal stimulation parameters are unknown. We recently completed a randomized, double blind clinical trial and a depression severity biomarker that predicts clinical outcome. The overarching goal of this study is to develop the first broadly generalizable platform for real-time biomarker monitoring and personalized rTMS treatment. We plan to recruit patients with medication-resistant depression and in perform a four-phase, cross-over, double-blind, placebo-controlled trial to 1) identify how standard and optimized rTMS patterns engage the depression severity biomarker, and 2) determine the dose-response of these rTMS patterns. Findings from this study will provide the basis for a double-blind, randomized clinical trial comparing rTMS optimized to the individual against standard rTMS.

Primary Outcome

Change in TMS-EEG measures will be assessed before, during, and after each rTMS session. Specifically, the amplitude of the change 30ms after a single TMS pulse in the frontoparietal region will be quantified. Brain changes will be compared between closed- loop, open-loop, and sham rTMS to identify the location, strength, and dose response of change for each condition.

Conditions Studied

Interventions

  • DEVICE sham rTMS
  • DEVICE closed-loop rTMS
  • DEVICE open-loop rTMS

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2021-06-01
Est. Completion 2025-12-01
Phase NA
Stanford University

1,744 total trials

What NCT04142320 shows while recruiting

NCT04142320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 3 interventions - of which sham rTMS is the first listed.

NCT04142320 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04142320 about?

NCT04142320 is a clinical study titled "Closed-loop Optimized rTMS for Depression". Targeted and individualized treatments for mental health disorders are critically needed. Repetitive transcranial magnetic stimulation (rTMS) represents the front-line of new and innovative approaches to normalizing dysfunctional brain networks in those with mental illness. rTMS is FDA-approved for ...

What is the current status of trial NCT04142320?

This trial is currently recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2021-06-01. Estimated completion is 2025-12-01.

What conditions does trial NCT04142320 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT04142320?

The interventions under investigation include: sham rTMS (DEVICE), closed-loop rTMS (DEVICE), open-loop rTMS (DEVICE).

Who is sponsoring clinical trial NCT04142320?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04142320 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04142320's enrollment target sits among peer trials

54 177th of 282 higher than 104 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04142320, the US trial registry maintained by the National Library of Medicine. NCT04142320 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.